AGC
8.12.2022 16:01:35 CET | Business Wire | Press release
AGC, the provider of a wide range of solutions from automotive and display glass to the cutting-edge materials essential for next-generation mobility, will exhibit at CES2023, the world's leading technology trade show, being held in Las Vegas during January 3-8, 2023. The 3rd and 4th will be reserved for media and pre-show keynotes; the fair will be open to the public from the 5th. The company will exhibit 17 of its products, including several brand new releases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221204005064/en/
AGC‘s booth at CES2023 (#4377, Vehicle Tech & Advanced Mobility, LVCC - West Hall) (Graphic: Business Wire)
AGC has been a leading manufacturer of architectural, automotive and display glass for more than 110 years, supplying high-quality products worldwide. Today, the company leverages its technological expertise in the fields of glass, electronics, chemicals, and ceramics to provide a variety of cutting-edge materials and services that meet the growing demand for autonomous driving and other mobility services.
One of the highlights of AGC’s exhibits at CES will be the company’s FIR (far infrared) camera-compatible windshield, featuring special glass that allows far-infrared rays to penetrate, something which ordinary automotive glass does not. This allows sensor fusion of regular visible and FIR cameras mounted behind the windshield and reduces the risk of accidents involving pedestrians and cyclists at night or in bad weather.
Another highlight of the exhibit will be AGC’s glass composition and processing technologies; these provide the strength and optical capabilities needed to mount and deploy the cameras and the LiDAR (light detection and ranging) components required for autonomous driving. A wide range of other solutions will also be exhibited, including the 5G-sub6 Glass Antenna and the 3D Curved Cover Glass For Automotive Interior Displays. For a complete list, please refer to the Appendix.
Yoshinori Hirai, President & CEO of AGC, commented, “CES is one of the world's most influential technology trade shows, and we see it as the best stage on which to showcase AGC's capabilities to the world. We strongly believe our next-generation mobility-related products and solutions will create a buzz among CES visitors. The materials we offer have an appeal that can only be successfully conveyed when they are seen and experienced up close. We hope that as many people as possible will learn firsthand about the value we offer and make good use of our products.”
Please stop by our booth and see the various ways in which AGC is pushing the boundaries of technology. If you would like to interview an AGC spokesperson, please contact us.
Booth information
LVCC - West Hall
Vehicle Tech & Advanced Mobility
#4377
In the same West Hall there will be a separate booth (#6557) dedicated to our "Wideye" solutions and another for our "FeelinGlass" product (#6674).
About CES
Owned and produced by the Consumer Technology Association (CTA)®, CES® is the world’s most influential tech event; the proving ground for breakthrough technologies and global innovators where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. CES 2023 will showcase the latest technological innovations dedicated to addressing the world’s most pressing global challenges in support of the United Nations’ efforts to advance human security for all. Please visit https://www.ces.tech/ for further details.
About AGC Inc.
AGC Inc. (Headquarters: Tokyo, President & CEO: Yoshinori Hirai) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Building on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The Group employs some 56,000 people worldwide and generates annual sales of around 1.7 trillion Japanese yen (approx. US$ 12.3bn) through its operations in more than 30 countries and regions. For more information, please visit https://www.agc.com/en/index.html
Appendix (List of exhibited products and technologies)
Product Name |
Brand name |
Usage/Application |
Appearing for the first time? |
Features |
FIR (far infrared) camera-compatible windshield |
|
Automotive windshields |
Yes |
|
5 G-sub 6 Glass Antenna |
|
Automotive Glazing |
Yes |
|
3D Curved Cover Glass
|
|
Automotive Interior Display
|
No |
Anti-reflection / Anti-fingerprint coating |
Porous Aminosilica |
|
CO2 Direct Air Capture (DAC) / Acid gas removal /
|
Yes |
|
Thermal Conductive-Electrical Insulation Film |
|
Thermal interface material for power semiconductors |
Yes |
|
Super-Hydrophobic Glass |
|
Window and roof glass for mobility applications;
|
Yes |
|
Windshield damage detection smart sensor |
Jack by AGC |
Self-powered device that detects, diagnoses and notifies in real-time glass damage to windshields |
Prototype has been previously presented |
|
Glass B-Pillar With Invisible Sensor Integration |
Wideye by AGC |
Lateral integration of a LiDAR sensor in a B-Pillar made of infrared transparent glass |
Prototype has been previously presented |
|
Cover Glass |
EG-A1, EG-A2 |
LiDAR, Camera |
Yes |
|
Aspherical Glass Lenses |
Aspherical Glass Molded Lenses |
LiDAR, Camera, Projector, Optical communication, AR/VR/MR, Lighting |
No |
|
Optical Filter |
IR Pass Filter, Band Pass Filter, Mirror |
Cover/noise removal for LiDAR, Camera, UV disinfection, semiconductor manufacturing |
No |
|
Glass Ceramics Substrate |
GCHPTM |
LEDs, semiconductors, lasers |
No |
|
DOE and Diffuser |
DOE and diffuser |
ToF sensor, LiDAR, cameras, projectors, optical communication, AR/VR/MR, lighting |
No |
|
Anti-glare glass |
New AG (anti-glare) glass for high-definition panels |
High-definition notebook PCs, tablets and monitors |
Yes |
|
Chemically engineered high strength glass |
Dragontrail |
Cover glass for displays of smartphones, tablets, PCs, etc. (electronic devices requiring cover glass) |
No |
|
FWA antenna |
"5G Millimeter Wave Transparent Antenna for FWA " |
Antenna is thin and transparent,
|
No |
|
Transparent Reflector Fence |
|
Local 5G networks |
Yes (overseas) |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221204005064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom